Genoptix — 2010 UBS Global Life Sciences Conference
23 slides from Genoptix's conference presentation, Sep 21, 2010
Slide 1: 2010 UBS Global Life Sciences Conference
2010 UBS Global Life Sciences Conference New York, NY Tina Nova, Ph.D. President & CEO Sam Riccitelli EVP & COO Exhibit 99.1 September 2010
Slide 2: Safe Harbor Statement
2 Forward-looking statements contained in this presentation involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forw
Slide 3: Genoptix Medical Laboratory
GENOPTIX MEDICAL LABORATORY
Slide 4: Slide 4
Slide 5: Slide 5
Slide 6: Genoptix At-A-Glance
3 Nasdaq Global Select, S&P Small Cap 600 Index, Russell 2000 ® Index Specialized, differentiated laboratory service provider profitable with positive cash flows since 2007 Addressing unmet diagnostic needs in hematology and oncology Addressing unmet needs in predictive therapeutics for solid tumor
Slide 7: The Genoptix Way
4 Genoptix One Patient One Hempath One Diagnosis PCR Cytogenetics/FISH Flow & Morphology Comprehensive And Integrated Diagnosis Community Hem/Onc Office * Final diagnosis * Treatment begins The Genoptix Way Hempath Consultation
Slide 8: Inadequacies of Traditional Testing
5 Results from 409 leukemia cases referred to MDACC: of cases were overturned due to a wrong diagnosis of cases required a change in treatment and/or prognosis of cases required a repeat bone-marrow and re-test Impact on patients and increase in costs: Repeat bone marrow testing Inappropriate drug t
Slide 9: GXDX Business Update
6 3Q10 case volumes and revenues expected to be 5-10% below prior quarter (2Q10) Economics continue to drive change in patient profile and trends in physician practice management Increasing competitive activity leading to market saturation, slowing rate of new customer acquisition Number of actively
Slide 10: Hematopathology Testing Market Is Stable But…
7 Changing patient profile – Number of uninsured at all time high – High deductible plans and increased cost of coinsurance reducing patient utilization of physician services (2) Physicians experimenting with – Selling to hospital or management companies (3) – Creative revenue sharing between labs &
Slide 11: COMPASS & CHART: The Transformation of Hematomalignancy DX
8 10 Convenient 11 Complementary Combines multiple COMPASS reports Extends our personalized medicine/service model Integrates intervening clinical actions Provides a complete clinical picture Provides hem/onc with valuable, specialized diagnostic tool to track individual patient’s response to treatm
Slide 12: Oncologists Value the Benefits of Genoptix
9 Hem/Oncs Using Genoptix Services 0 200 400 600 800 1000 1200 1400 Oncologists Value the Benefits of Genoptix
Slide 13: Addressing Challenges In The Marketplace
10 Increase in regional competitiveness Adding depth to sales coverage, leveraging reputation for quality offering Product imitation by competitors Differentiating by adding new tests and proprietary offerings Competitive EMR purchases Strategic EMR support for key accounts Weakened sales force effe
Slide 14: New Products & Services
11 Multiple Myeloma MRD - iFISH of Minimum Residual Disease (MRD) with immuno- enrichment over conventional cytogenetics (iFISH) of disease progression for Colorectal carcinomas Help options with physician customers Extends the Genoptix service approach to expected in 2011 New Products & Services En
Slide 15: Reimbursement And Payor Relationships
12 Non- contracted Contracted Contracted business – ~ 40% Medicare – ~ 20% major payors expected by Y/E 2010 Non-Contracted business – Reimbursed by payors as an out-of-network provider – Bill patient co-insurance and deductibles at in-network rates, as permitted by law Evolution Of Payor Mix – Sign
Slide 16: Putting Capital to Work
13 Reinvesting income to build long-term value Increasing operational capacity Assessing various opportunities through intensive evaluation – Technologies – Partnerships – Acquisitions Several strategies/opportunities under consideration – Expansion of solid tumor testing capabilities – Accessing ne
Slide 17: A Large And Growing Market
14 ~ 8% Incidence Rates 375,000 bone marrows/yr 250,000 related blood-based tests/yr Hem/Onc Physicians 12,500 hem/oncs 9,500, or 76%, practice in the community setting Patients 850,000 patients in the U.S. 150,000 new cases annually = Market Share = Market Share Projection by 2015 Genoptix’ goal is
Slide 18: Genoptix Medical Laboratory
GENOPTIX MEDICAL LABORATORY
Slide 19: Growth Profile
EE ee Growth Profile = B= _<=& $50.9M 2070 wi ~$1.8M A in estimates mE =feleE . ~12% increase YW from 2Q 2009 ait. ~ 7% increase Q/Q from 1Q 2010 =e $0.31 EPS 2Q10 at 48% tax rate == be 3 mE Zz 3 se PP PP PPP OP PD ses wo eS ee ES ES EK SS Bin thowsarcy) GENOPTIX AL LABORATOR 16
Slide 20: Committing To Next Phase Of Growth
17 Laboratory Capacity Expansion – Grow HemPath team to 50 by Y/E – Additional lab support personnel – New laboratory opened in July ($0.10) Sales & Marketing Expansion – Grow Sales team to 100 by Y/E – New Customer Service facility in 4Q – Selective investments in client EMR ($0.09) Growth Investme
Slide 21: Financial Summary
18 ($ in thousands) 2009 2010 Revenues $84,487 $98,336 YOY Growth -- 16% Cost of Revenues 32,201 39,245 Gross Profit $52,286 $59,091 % Gross margin 62% 60% Operating Expenses: Sales & Marketing 14,321 20,851 Sales & Marketing % of Rev 17% 21% General & Administrative 13,881 17,465 G&A as % of Rev 16
Slide 22: Summary
19 Targeting share by 2015 service offerings are in the United States and spurring competitors to emulate our success Continue to strengthen sales organization to convey value proposition and combat new entrants, targeting by end of 2010 on community hem/onc driving and we are evolving as appropriat
Slide 23: Genoptix Medical Laboratory
GENOPTIX MEDICAL LABORATORY